Home » UPC decisions » Local Division » LD The Hague, November 10, 2026, Decision of the Court of First Instance, UPC_CFI_620/2025, UPC_CFI_1509/2025, UPC_CFI_1511/2025

LD The Hague, November 10, 2026, Decision of the Court of First Instance, UPC_CFI_620/2025, UPC_CFI_1509/2025, UPC_CFI_1511/2025

3 min Reading time

Key takeaways

Claimed numerical ranges must be read with the description

Headnote 2. The claimed range of pKa 5.0-6.8 is not to be interpreted as containing rigid cut-off limits in the present case. The claim, which includes a specific measurement method, should be read together with the description which contains a reference to a measurement imprecision for this method of +/-0.2 pKa units.

Novelty, unambiguous disclosure of feature combination in the prior art

Features mentioned in a prior art document can only be used for novelty objections if their combination was originally disclosed. Same standard as applied to clear and unambiguos disclosure for claim amendments.

Corresponding headnote: 5. For the assessment of novelty, the claims of a prior art patent or patent application form an integral part of its technical disclosure and must be read together with the description. This does however not mean that any combination of (features from) claims of a prior art patent necessarily forms a direct and unambiguous disclosure of the subject-matter of this combination, in particular if the combination implies a(n arbitrary) selection. When the combination is not unambiguously derivable for the skilled person, it is not an enabling disclosure that anticipates the patent at issue. What matters is whether the skilled person understands that such an assembly of (features from) claims is disclosed and reflects the technical teaching of the document (see EPO BoA T 1658/12).

Common general knowledge under Art. 56 EPC requires factual information that is elementary, convincing, and consensual, with the burden of proof resting strictly on the asserting party

Generally, common general knowledge is formed by textbooks used as introduction to a field of technology. Scientific papers, e.g. review articles, may form common general knowledge, but only if it can be assumed that the contents of the papers represent consensus within the scientific community. In the current case, the defendants failed to establish that liposomal mRNA encapsulation was common general knowledge at the priority date. The court held that inclusion in specialized review articles does not suffice without evidence of widespread community consensus.

Corresponding Headnote: 6. Common General Knowledge (CGK) is not primarily related to a specific document, but rather to a specific knowledge. This knowledge is typically found in textbooks that introduce the field of technology in question. For information to qualify as CGK, it should be present in more than one document. In highly specialised areas, the document may be a review article, handbook or handbook chapter. However, the issue is not whether the information asserted to be CGK is contained in a well-known and widely accepted document. To determine the scope of CGK, the real issue is whether the relevant factual information is so elementary, convincing and consensual that a person skilled in the relevant field will necessarily know it and whether the relevant community has accepted it as an established empirical fact.

Division

Local Division The Hague

UPC number

UPC_CFI_620/2025; UPC_CFI_1509/2025; UPC_CFI_1511/2025

Type of proceedings

Infringement action, counterclaims for revocation, and application to amend the patent

Parties

Claimant / Defendant in the Counterclaim: GlaxoSmithKline Biologicals SA

Defendants / Counterclaimants:

C.P. Pharmaceuticals International C.V. (the Netherlands) and subsidiaries/associated firms

BioNTech SE (Germany) and subsidiaries/associated firms

Patent(s)

EP 2 590 626

Jurisdictions

UPC

Body of legislation / Rules

Rule 13.1 RoP

Rule 25.1 RoP

Rule 42.1 RoP

Rule 63 RoP

Rule 105.5 RoP

Rule 170.1 RoP

Rule 171.1, 171.2 RoP

Rule 179 RoP

Rule 181 RoP

Art. 24 UPCA

Art. 65 UPCA

Art. 69 EPC


Was the article helpful?


Categories


Tags

  • Dr. Philipp Bovenkamp, German and European Patent Attorney, UPC Representative, Counsel at BARDEHLE PAGENBERG

    German and European Patent Attorney, UPC Representative, Counsel

  • Karin Bek, Attorney-at-Law (Rechtsanwältin), UPC Representative

    Attorney-at-Law (Rechtsanwältin), UPC Representative

Stay in the loop

Never miss a beat by subscribing to the email newsletter. Please see our Privacy Policy.

* = Required field